UroGen Pharma (NASDAQ:URGN) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research note released on Thursday, Benzinga reports. The brokerage currently has a $54.00 price objective on the stock.

Separately, Oppenheimer dropped their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an outperform rating on the stock in a research note on Friday, March 15th.

UroGen Pharma Price Performance

URGN traded up $0.02 during trading on Thursday, reaching $14.26. 315,324 shares of the stock traded hands, compared to its average volume of 343,932. The stock's 50-day simple moving average is $16.30 and its two-hundred day simple moving average is $14.59. UroGen Pharma has a fifty-two week low of $8.69 and a fifty-two week high of $24.13. The stock has a market cap of $334.40 million, a price-to-earnings ratio of -3.82 and a beta of 1.07.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.05). The firm had revenue of $23.53 million during the quarter, compared to the consensus estimate of $22.30 million. Research analysts anticipate that UroGen Pharma will post -3.59 earnings per share for the current fiscal year.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 3,789 shares of the firm's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total value of $59,638.86. Following the transaction, the insider now directly owns 149,423 shares of the company's stock, valued at approximately $2,351,918.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other UroGen Pharma news, General Counsel Jason Drew Smith sold 4,993 shares of the company's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $78,589.82. Following the completion of the sale, the general counsel now directly owns 18,824 shares in the company, valued at $296,289.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 3,789 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $59,638.86. Following the sale, the insider now owns 149,423 shares of the company's stock, valued at approximately $2,351,918.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,782 shares of company stock worth $306,829. 11.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc raised its position in shares of UroGen Pharma by 34.6% during the fourth quarter. Legal & General Group Plc now owns 2,868 shares of the company's stock valued at $43,000 after buying an additional 738 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in UroGen Pharma by 1.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 86,109 shares of the company's stock valued at $1,206,000 after acquiring an additional 1,069 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in UroGen Pharma by 31.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company's stock valued at $74,000 after acquiring an additional 1,191 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of UroGen Pharma by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 46,394 shares of the company's stock worth $650,000 after acquiring an additional 1,670 shares during the period. Finally, Boothbay Fund Management LLC grew its holdings in shares of UroGen Pharma by 17.4% during the 1st quarter. Boothbay Fund Management LLC now owns 13,075 shares of the company's stock worth $121,000 after purchasing an additional 1,936 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.